Skip to main content
Carisma Therapeutics Inc. logo

Carisma Therapeutics Inc. — Investor Relations & Filings

Ticker · CARM ISIN · US14216R1014 LEI · 549300DGKHONOZQIY116 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2024-07-09 Regulatory Filings
Country US United States of America
Listing US CARM

About Carisma Therapeutics Inc.

https://sesenbio.com/

Carisma Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of engineered macrophage-based therapeutics. The company's proprietary cell therapy platform is centered on Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes. This approach is designed to leverage the unique abilities of macrophages to infiltrate solid tumors, overcome the immunosuppressive tumor microenvironment, and stimulate a broad anti-tumor response. Carisma's pipeline is focused on developing treatments for cancer and other serious disorders, including fibrosis.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes an announcement of new analysis related to a Phase 1 clinical trial and a presentation excerpt attached as an exhibit. It does not contain full financial statements or detailed financial performance data. The document is not an Annual Report, Interim Report, or Earnings Release. It is not a proxy, voting result, or management change announcement. The document is primarily an announcement of clinical trial data and a presentation excerpt, which fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories. The document length is about 5251 characters, which is not extremely short, but the content is clearly an 8-K current report announcing other events and attaching a presentation excerpt, not the presentation itself or a full report. Therefore, the best classification is Regulatory Filings (RNS).
2024-07-09 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the termination of a Manufacturing and Supply Agreement, a termination fee, and changes in the company's operating plan. There are no financial statements or detailed financial performance data included. The document is not an Annual Report, Interim Report, Earnings Release, or any detailed financial report. It is a regulatory announcement of a significant corporate event. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-07-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-07-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-07-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-07-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-07-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.